AU2014240467B2 - Regulation of cancer using natural compounds and/or diet - Google Patents

Regulation of cancer using natural compounds and/or diet Download PDF

Info

Publication number
AU2014240467B2
AU2014240467B2 AU2014240467A AU2014240467A AU2014240467B2 AU 2014240467 B2 AU2014240467 B2 AU 2014240467B2 AU 2014240467 A AU2014240467 A AU 2014240467A AU 2014240467 A AU2014240467 A AU 2014240467A AU 2014240467 B2 AU2014240467 B2 AU 2014240467B2
Authority
AU
Australia
Prior art keywords
cancer
tumor
mkd
cell
hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014240467A
Other languages
English (en)
Other versions
AU2014240467A1 (en
Inventor
Loic DELEYROLLE
Brent Reynolds
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of AU2014240467A1 publication Critical patent/AU2014240467A1/en
Application granted granted Critical
Publication of AU2014240467B2 publication Critical patent/AU2014240467B2/en
Priority to AU2019201369A priority Critical patent/AU2019201369A1/en
Priority to AU2020223647A priority patent/AU2020223647A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/055—Organic compounds containing sulfur as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
AU2014240467A 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet Ceased AU2014240467B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2019201369A AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784386P 2013-03-14 2013-03-14
US61/784,386 2013-03-14
PCT/US2014/023934 WO2014159500A1 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201369A Division AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet

Publications (2)

Publication Number Publication Date
AU2014240467A1 AU2014240467A1 (en) 2015-11-05
AU2014240467B2 true AU2014240467B2 (en) 2018-11-29

Family

ID=51625178

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014240467A Ceased AU2014240467B2 (en) 2013-03-14 2014-03-12 Regulation of cancer using natural compounds and/or diet
AU2019201369A Abandoned AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A Abandoned AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2019201369A Abandoned AU2019201369A1 (en) 2013-03-14 2019-02-27 Regulation of cancer using natural compounds and/or diet
AU2020223647A Abandoned AU2020223647A1 (en) 2013-03-14 2020-08-25 Regulation of cancer using natural compounds and/or diet

Country Status (9)

Country Link
US (2) US20160038456A1 (https=)
EP (1) EP2968260B1 (https=)
JP (2) JP6488276B2 (https=)
CN (2) CN105377252A (https=)
AU (3) AU2014240467B2 (https=)
BR (1) BR112015023190A2 (https=)
CA (1) CA2912518A1 (https=)
IN (1) IN2015DE09621A (https=)
WO (1) WO2014159500A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
KR20180014194A (ko) * 2015-06-26 2018-02-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법
CN107921133A (zh) * 2015-09-04 2018-04-17 国立大学法人大阪大学 癌症的饮食疗法开发
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
CN108192866B (zh) * 2018-03-07 2021-05-11 郑州大学第一附属医院 Sfn联合il-15和il-21制备记忆性t细胞的方法及应用
KR102174166B1 (ko) * 2018-12-13 2020-11-04 영남대학교 산학협력단 호모해링토닌을 유효성분으로 함유하는 세포노화 관련 질환 예방 또는 치료용 조성물
CN110420178B (zh) * 2019-09-11 2022-08-05 长江师范学院 一种胭脂萝卜硫苷水凝胶的制备方法
EP3861992B1 (en) * 2020-02-07 2023-09-06 CannaFamily a.s. Combination therapy comprising plant derived compounds and antineoplastic compounds for treatment of hematological malignancies
JP7727286B2 (ja) * 2020-09-23 2025-08-21 アミノヴィタ エセ．エレ． 癌の代謝療法
TW202339712A (zh) * 2022-01-24 2023-10-16 國立大學法人大阪大學 用於治療癌症之組合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113572A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725895B1 (en) * 1995-09-15 2000-10-10 Hopkins J School Of Medicine Method of preparing food product from cruciferous seeds
US6242018B1 (en) * 1997-04-11 2001-06-05 Johns Hopkins School Of Medicine Cancer Chemoprotective food products
JPH1149793A (ja) * 1997-08-08 1999-02-23 Momoya:Kk 野菜由来の抗腫瘍性物質
CN1141092C (zh) * 2001-01-19 2004-03-10 郭兴华 一种防治骨质疏松、癌症和降血脂组合物及其应用
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US20090143433A1 (en) 2004-12-01 2009-06-04 Curt Hendrix Cocktail for modulation of alzheimer's disease
JP2007153834A (ja) * 2005-12-07 2007-06-21 Univ Kansai カイワレ大根由来の不凍活性を有する抽出物、その製造方法、ならびにその用途
WO2009051739A1 (en) 2007-10-16 2009-04-23 Johns Hopkins University Methods for protecting the skin from radiation insults
US20090252758A1 (en) * 2008-04-07 2009-10-08 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
AR084174A1 (es) 2010-12-21 2013-04-24 Lilly Co Eli Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica
DE102011008016A1 (de) * 2011-01-06 2012-07-12 Johannes F. Coy Schokoladenmasse
DE102011008017A1 (de) 2011-01-06 2012-07-12 Johannes F. Coy Erfrischungsgetränk
WO2012142511A2 (en) 2011-04-15 2012-10-18 Md Matrix Health Llc Dba Md Matrix Health Inc Orthomolecular compositions and their use in stabilizing the extracellular matrix
WO2012159085A2 (en) * 2011-05-19 2012-11-22 Glax L.L.C. Compositions and methods for treating and preventing cancer by targeting and inhibiting cancer stem cells
GB201210699D0 (en) 2012-06-15 2012-08-01 Vitaflo Ltd Nutritional food
US10960057B2 (en) 2012-07-05 2021-03-30 Nutramax Laboratories, Inc. Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder
US20140275235A1 (en) 2013-03-15 2014-09-18 Loic Pierre Deleyrolle Treatment of Proliferative Disorders
CA2904865A1 (en) 2013-03-15 2014-10-16 Nutramax Laboratories, Inc. Sulforaphane/sulforaphane precursor and phytosterol/phytostanol compositions
KR102499654B1 (ko) 2013-03-19 2023-02-13 유니버시티 오브 사우스 플로리다 상승되고 지속되는 케톤증을 생성하기 위한 조성물 및 방법
CA2910546C (en) 2013-05-14 2023-03-28 Mars, Incorporated Joint care composition
US20130310457A1 (en) 2013-07-25 2013-11-21 Niral Ramesh Solid-in-oil dispersions
WO2015034812A2 (en) 2013-09-04 2015-03-12 Beth Israel Deaconess Medical Center A new ketogenic diet and its use in treating the critically ill
US11020372B2 (en) 2015-03-24 2021-06-01 University Of Florida Research Foundation, Incorporated Dietary and natural product management of negative side effects of cancer treatment
KR20180014194A (ko) 2015-06-26 2018-02-07 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 천연 화합물 및/또는 식단을 사용하는 염증의 치료 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012113572A1 (en) * 2011-02-24 2012-08-30 N.V. Nutricia Ketogenic diet composition for the treatment of chemo therapy and/or radiation therapy patients
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALESSIO PAPI ET AL, "Cytotoxic and Antioxidant Activity of 4-Methylthio-3-butenyl Isothiocyanate from Raphanus sativus L. (Kaiware Daikon) Sprouts", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, (2008-02-01), vol. 56, no. 3, pages 875 - 883. *
CHRISTOPH OTTO ET AL, "Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides", BMC CANCER, (2008-04-30), vol. 8, no. 1, page 122. *
FAROOQI AMMAD AHMAD ET AL, JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, vol. 9, no. 3, (2011-01-01), pages 201 - 206. *
KRISTIN W. BARAÑANO ET AL, "The ketogenic diet: Uses in epilepsy and other neurologic illnesses", CURRENT TREATMENT OPTIONS IN NEUROLOGY, (2008-11-01), vol. 10, no. 6, pages 410 - 419. *
MAALOUF M ET AL, "The neuroprotective properties of calorie restriction, the ketogenic diet, and ketone bodies", BRAIN RESEARCH REVIEWS, vol. 59, no. 2, (2009-03-01), pages 293 - 315. *
NATALIE A KELSEY ET AL, "Nutraceutical antioxidants as novel neuroprotective agents", MOLECULES: A JOURNAL OF SYNTHETIC ORGANIC AND NATURAL PRODUCT CHEMISTRY, (2010-11-03), vol. 15, no. 11, pages 7792 - 7814. *
SEYFRIED THOMAS N ET AL, Targeting Energy Metabolism in Brain Cancer with Restricted Diets, GLIOBLASTOMA: MOLECULAR MECHANISMS OF PATHOGENESIS AND CURRENT THERAPEUTIC STRATEGIES, PAGES 341 - 363. (2010-01-01). *

Also Published As

Publication number Publication date
CA2912518A1 (en) 2014-10-02
EP2968260A1 (en) 2016-01-20
US20160038456A1 (en) 2016-02-11
US20210008024A1 (en) 2021-01-14
US11666549B2 (en) 2023-06-06
IN2015DE09621A (en) 2016-02-26
CN110420329A (zh) 2019-11-08
WO2014159500A1 (en) 2014-10-02
AU2020223647A1 (en) 2020-09-10
CN105377252A (zh) 2016-03-02
JP2016514135A (ja) 2016-05-19
JP6488276B2 (ja) 2019-03-20
EP2968260A4 (en) 2017-05-10
EP2968260B1 (en) 2020-12-16
JP2018162248A (ja) 2018-10-18
AU2019201369A1 (en) 2019-03-21
AU2014240467A1 (en) 2015-11-05
BR112015023190A2 (pt) 2017-07-18

Similar Documents

Publication Publication Date Title
US11666549B2 (en) Regulation of cancer using natural compounds and/or diet
US11020372B2 (en) Dietary and natural product management of negative side effects of cancer treatment
JP2017171683A (ja) Ｒａｇｅ遺伝子発現抑制剤
US12589088B2 (en) Compositions and methods for treating cancer with andrographolide and melatonin combination therapy
KR20240040430A (ko) 아피제닌을 포함하는 대장암 예방 또는 치료용 약학적 조성물
KR101184152B1 (ko) 항산화 단백질 엔알에프-2의 활성 증진, 간염 치료 및 예방 또는 간 보호에 유용한 3, 4-디히드록시벤잘아세톤
CN106999525A (zh) 用于治疗间皮瘤的菜蓟滴定提取物
Blanke et al. A phase I study of vitamin E, 5-fluorouracil and leucovorin for advanced malignancies
KR101613005B1 (ko) 항암제에 의해 유발되는 신장 독성 질환의 예방 및 치료용 약학적 조성물
Walstad-Terpak Nutrition and Supplements as Chemoprevention for Reducing the Risk of Nonglandular Oral and Oropharyngeal Cancers of the Head and Neck
Gatica et al. Effect of music on 400-m sprint running performance in healthy subjects
Gillen et al. Short-Term High-Intensity Interval Training Reduces Hyperglycemia in Type 2 Diabetics
Stokes et al. No Effect Of Cigarette Smoking On Calf Muscle Size And Density Changes Following Military Training
Gorres et al. Activation of Estrogen Receptor· Potentiates Insulin-stimulated Glucose Uptake into Skeletal Muscle of Female Rats
Kellawan et al. Does Oxygen Delivery Predict Performance During An" All-Out" Critical Power Test?
Ribeiro et al. Exercise Training Improves Autonomic Function After an Acute Myocardial Infarction
Welc et al. Heat Stroke Up Regulates Interleukin-6 In Skeletal Muscle.
Chung et al. Pregnancy and Exercise-induced Cardiac Hypertrophy are Distinct
Hoshino et al. High-intensity Interval Training Increases The Rate Of Mitochondrial Fatty Acid Oxidation in skeletal muscle
Kump Gamma-MSH Fails to Increase Cell Growth or Differentiation of C2C12 Myotubes
Harris et al. The Association between Flow-Mediated Dilation and Oxidative Stress in Response to Acute Exercise
Koulmann et al. Recovery Of Skeletal Muscle Phenotype After Notexin Injury: Positive Effects Of Running Exercise.
Galassetti et al. Effect of Fat Ingestion on Myeloperoxidase; an Exercise Study in Healthy and Obese Children
Moore-Harrison et al. Nhlh2 and Lepr Gene Expression in High and Low Physical Activity Mice
Reed et al. Foxo Activity is Required for the Normal Muscle Atrophy Program during Cancer Induced Cachexia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired